BEIJING, March 27, 2026 — Sinovac Holding Group (“SINOVAC”) and Bio Farma, Indonesia's state-owned pharmaceutical company, signed a strategic memorandum of understanding in Beijing on March 27, 20

BEIJING, January 27, 2026 – Co-administration of SINOVAC's Sabin-strain inactivated poliovirus vaccine (sIPV) with either measles-mumps-rubella (MMR) or inactivated hepatitis A (HepA) vaccines is

BEIJING, January 22, 2026 – Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Nasdaq Hearings Panel (

BEIJING, January 20, 2026 – A large-scale real-world study published in the peer-reviewed journal Vaccines showed that SINOVAC's live attenuated varicella vaccine (VarV) has a stable and favorable

BEIJING, January 20, 2026 – Co-administration of SINOVAC’s live attenuated varicella vaccine (VarV) and trivalent inactivated influenza vaccine (Anflu®) was shown to be safe and immunogenic in in heal

BEIJING, Jan. 7, 2026 – On January 6, 2026, Sinovac Life Sciences Co., Ltd., a subsidiary of Sinovac Biotech Ltd. (“SINOVAC” or the “Company”), initiated the enrollment of volunteer subjects for a Pha

BEIJING--Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today provided an update on the Antigua High Co

BEIJING -- Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced that the Antigua High Court has ordered that the dire

BEIJING, Jan. 4, 2026 — SINOVAC Biotech Ltd. ("SINOVAC" or the "Company"), a leading global provider of biopharmaceutical products, has been awarded an exclusive contract under the

BEIJING, Dec. 29, 2025 – Sinovac Biotech Ltd. ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, recently announced the commercial launch of i

DALIAN, China, Dec. 17, 2025 – Sinovac Biotech Ltd. ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced that the live attenuated vari

BEIJING, Dec. 16, 2025 – Results from a Phase III clinical study evaluating both humoral and cellular immune responses induced by SINOVAC's quadrivalent influenza vaccine (Sinovac-QIV) have been p

SÃO PAULO, Nov. 25, 2025 — Sinovac Biotech Ltd. ("SINOVAC" or the "Company"), a leading global provider of biopharmaceutical products, has entered into a long-term strategic cooper

BEIJING, Nov. 7, 2025 — SINOVAC Biotech Ltd. ("SINOVAC" or the "Company"), a leading global provider of biopharmaceutical products, today announced that its live attenuated varicel

BEIJING, October 30, 2025 – Sinovac Biotech Ltd. ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the National Medical

BEIJING, Oct. 25, 2025 – A head-to-head Phase III clinical trial published in Vaccines showed that SINOVAC's varicella vaccine had a more favorable safety profile than a WHO-prequalified comparato

BEIJING, Oct. 10, 2025 – SINOVAC's quadrivalent influenza vaccine, produced by its subsidiary Beijing Sinovac Biological Products Co., Ltd., has received approval from the National Medical Product

BEIJING, September 1, 2025 – SINOVAC's 23-valent pneumococcal polysaccharide vaccine (PPSV23) induces a significant immune response and maintains a favorable safety profile in individuals aged two

BEIJING, Aug. 29, 2025 — SINOVAC Biotech Ltd. ("SINOVAC" or the "Company"), a leading global provider of biopharmaceutical products, hosted the 2025 Supply Chain Eco-Conference at

BEIJING, August 14, 2025 – the immunogenicity and safety profiles of SINOVAC's quadrivalent influenza vaccine (IIV4) and 23-valent pneumococcal polysaccharide vaccine (PPSV23), particularly when a